349 related articles for article (PubMed ID: 33926608)
21. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.
Drugs R D; 2003; 4(5):312-9. PubMed ID: 12952502
[TBL] [Abstract][Full Text] [Related]
22. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
23. Prevalence of financial conflicts of interest among panel members producing clinical practice guidelines in Canada and United States: cross sectional study.
Neuman J; Korenstein D; Ross JS; Keyhani S
BMJ; 2011 Oct; 343():d5621. PubMed ID: 21990257
[TBL] [Abstract][Full Text] [Related]
24. Oncologic Drugs Advisory Committee Recommendations and Approval of Cancer Drugs by the US Food and Drug Administration.
Tibau A; Ocana A; Anguera G; Seruga B; Templeton AJ; Barnadas A; Amir E
JAMA Oncol; 2016 Jun; 2(6):744-50. PubMed ID: 26940233
[TBL] [Abstract][Full Text] [Related]
25. Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval.
Cherla A; Naci H; Kesselheim AS; Gyawali B; Mossialos E
JAMA Intern Med; 2021 Apr; 181(4):490-498. PubMed ID: 33616607
[TBL] [Abstract][Full Text] [Related]
26. Implementing the Biopharmaceutics Classification System in Drug Development: Reconciling Similarities, Differences, and Shared Challenges in the EMA and US-FDA-Recommended Approaches.
Cardot JM; Garcia Arieta A; Paixao P; Tasevska I; Davit B
AAPS J; 2016 Jul; 18(4):1039-46. PubMed ID: 27116020
[TBL] [Abstract][Full Text] [Related]
27. 2020 FDA Drug-drug Interaction Guidance: A Comparison Analysis and Action Plan by Pharmaceutical Industrial Scientists.
Sudsakorn S; Bahadduri P; Fretland J; Lu C
Curr Drug Metab; 2020; 21(6):403-426. PubMed ID: 32562522
[TBL] [Abstract][Full Text] [Related]
28. Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017.
Zhang AD; Puthumana J; Downing NS; Shah ND; Krumholz HM; Ross JS
JAMA Netw Open; 2020 Apr; 3(4):e203284. PubMed ID: 32315070
[TBL] [Abstract][Full Text] [Related]
29. The Food and Drug Administration reports provided more data but were more difficult to use than the European Medicines Agency reports.
Schroll JB; Abdel-Sattar M; Bero L
J Clin Epidemiol; 2015 Jan; 68(1):102-7. PubMed ID: 25150193
[TBL] [Abstract][Full Text] [Related]
30. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
[TBL] [Abstract][Full Text] [Related]
31. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
32. Update and trends on pharmacokinetic studies in patients with impaired renal function: practical insight into application of the FDA and EMA guidelines.
Paglialunga S; Offman E; Ichhpurani N; Marbury TC; Morimoto BH
Expert Rev Clin Pharmacol; 2017 Mar; 10(3):273-283. PubMed ID: 27998190
[TBL] [Abstract][Full Text] [Related]
33. Regional Differences During the ICH Regulatory Consultation Process Between the EU, US, and Japan.
Torqui A; Macau AM
Ther Innov Regul Sci; 2018 Jul; 52(4):438-441. PubMed ID: 29714552
[TBL] [Abstract][Full Text] [Related]
34. Preclinical efficacy in therapeutic area guidelines from the U.S. Food and Drug Administration and the European Medicines Agency: a cross-sectional study.
Langhof H; Chin WWL; Wieschowski S; Federico C; Kimmelman J; Strech D
Br J Pharmacol; 2018 Nov; 175(22):4229-4238. PubMed ID: 30153701
[TBL] [Abstract][Full Text] [Related]
35. Food for thought? Potential conflicts of interest in academic experts advising government and charities on dietary policies.
Newton A; Lloyd-Williams F; Bromley H; Capewell S
BMC Public Health; 2016 Aug; 16():735. PubMed ID: 27495802
[TBL] [Abstract][Full Text] [Related]
36. Outcome selection for tissue-agnostic drug trials for immune-mediated inflammatory diseases: a systematic review of core outcome sets and regulatory guidance.
Aiyegbusi OL; di Ruffano LF; Retzer A; Newsome PN; Buckley CD; Calvert MJ
Trials; 2022 Jan; 23(1):42. PubMed ID: 35033186
[TBL] [Abstract][Full Text] [Related]
37. [Procedures and methods of benefit assessments for medicines in Germany].
Bekkering GE; Kleijnen J
Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
[TBL] [Abstract][Full Text] [Related]
38. US FDA/EMA harmonization of their bioanalytical guidance/guideline and activities of the Global Bioanalytical Consortium.
Garofolo F; Michon J; Leclaire V; Booth B; Lowes S; Viswanathan CT; Welink J; Haidar S; Teixeira Lde S; Tang D; Desilva B
Bioanalysis; 2012 Feb; 4(3):231-6. PubMed ID: 22303826
[TBL] [Abstract][Full Text] [Related]
39. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome.
Teede HJ; Misso ML; Costello MF; Dokras A; Laven J; Moran L; Piltonen T; Norman RJ;
Fertil Steril; 2018 Aug; 110(3):364-379. PubMed ID: 30033227
[TBL] [Abstract][Full Text] [Related]
40. BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements.
Davit BM; Kanfer I; Tsang YC; Cardot JM
AAPS J; 2016 May; 18(3):612-8. PubMed ID: 26943914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
